Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease

NCT06610526 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06610526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06610526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Interventional, Multicentre, Phase IV, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Active, not recruiting
Start date
August 23, 2024
Completion date
May 31, 2027
Enrollment
731 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease